Cabio Biotech Wuhan Co Ltd
SSE:688089
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Investor AB
STO:INVE B
|
SE |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (58), the stock would be worth ¥63.42 (296% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 14.6 | ¥16.02 |
0%
|
| 3-Year Average | 58 | ¥63.42 |
+296%
|
| 5-Year Average | 55.5 | ¥60.68 |
+279%
|
| Industry Average | 38.3 | ¥41.85 |
+161%
|
| Country Average | 28.9 | ¥31.61 |
+97%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
¥3.2B
|
/ |
Oct 2025
¥173.6m
|
= |
|
|
¥3.2B
|
/ |
Dec 2025
¥198m
|
= |
|
|
¥3.2B
|
/ |
Dec 2026
¥240.4m
|
= |
|
|
¥3.2B
|
/ |
Dec 2027
¥288.9m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
C
|
Cabio Biotech Wuhan Co Ltd
SSE:688089
|
2.7B CNY | 14.6 | 15.9 | |
| US |
|
Sherwin-Williams Co
NYSE:SHW
|
83.6B USD | 24.8 | 32.6 | |
| JP |
|
Shin-Etsu Chemical Co Ltd
TSE:4063
|
12.5T JPY | 17.8 | 26.1 | |
| US |
|
Ecolab Inc
NYSE:ECL
|
76.6B USD | 28.8 | 36.9 | |
| JP |
Y
|
Yasuhara Chemical Co Ltd
TSE:4957
|
10.8T JPY | 7.1 | 10.5 | |
| CN |
|
Wanhua Chemical Group Co Ltd
SSE:600309
|
274.4B CNY | 18 | 20.8 | |
| CH |
|
Givaudan SA
SIX:GIVN
|
26B CHF | 21.5 | 24.2 | |
| IN |
|
Asian Paints Ltd
NSE:ASIANPAINT
|
2.4T INR | 45.6 | 61.7 | |
| DK |
|
Novozymes A/S
CSE:NZYM B
|
165.6B DKK | 37.9 | 54.8 | |
| US |
|
PPG Industries Inc
NYSE:PPG
|
24.6B USD | 13.5 | 15.6 | |
| CH |
|
Sika AG
F:SIKA
|
19.9B EUR | 14.2 | 17.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.6 |
| Median | 28.9 |
| 70th Percentile | 52.9 |
| Max | 49 021 |
Other Multiples
Cabio Biotech Wuhan Co Ltd
Glance View
Cabio Biotech Wuhan Co Ltd is a China-based company principally engaged in biotechnology business. The Company is mainly engaged in the research and development, production and sales of polyunsaturated fatty acids arachidonic acid (ARA), algal oil docosahexaenoic acid (DHA) and sialic acid (SA), and natural beta-carotene products. Its products are mainly used in infant formula food, dietary supplements, nutritional health food and formula food for special medical purposes. The Company integrates industrial strain-oriented optimization technology, fermentation fine control technology, and efficient separation, purification and preparation technology, and provides nutrient products and innovative solutions for customers in the global nutrition and health field through sustainable microbial synthesis and manufacturing methods. The Company mainly conducts its business in domestic and overseas markets.
